You are here
OncoSec Announces Poster Presentation at 2019 American Association for Cancer Research Annual Meeting
SAN DIEGO and PENNINGTON, N.J., Feb. 28, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing novel cancer immunotherapies, today announced it will present pre-clinical data regarding its new anti-tumor product candidate during a poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting, which will be held March 29 – April 3, 2019 at the Georgia World Congress Center in Atlanta, Georgia.
The poster is entitled, "Intratumoral administration of plasmid IL-12 and CXCL9 with membrane-bound anti-CD3 elicits robust anti-tumor immunity," and outlines pre-clinical data demonstrating that IL-12, in concert with CXCL9, inflames tumors. This leads to a brisk T cell infiltrate and anti-tumor activity, which when combined with anti-CD3 stimulation, drives a robust systemic T cell response. A link to the abstract of the presentation can be found here.
OncoSec's clinical studies have demonstrated that plasmid IL-12 (tavokinogene telseplasmid) delivered intratumorally (TAVO) induces local expression of IL-12, converting immunologically cold tumors into inflamed immunogenic lesions, which is fundamental to generating objective responses in both treated and untreated distant tumors. In order to identify the key immunological components associated with an effective therapy, OncoSec's research laboratory used immunological findings made from previously treated TAVO patients to design its new, second product candidate.
"This new product candidate builds upon our plasmid-based cancer immunotherapy platform by amplifying the power of intratumoral IL-12 through the addition of both CXCL9, a critical T cell chemokine, along with a membrane bound pan T cell stimulator, anti-CD3," noted Christopher Twitty, Ph.D., Chief Scientific Officer of OncoSec. "Importantly, this new product candidate integrates three key immunotherapeutic elements into a single novel, multi-gene expression platform that we believe has broad applicability across a number of tumor targets. We look forward to filing an Investigational New Drug application for this promising new product."
Presentation details are as follows:
Anandaroop Mukhopadhyay, PhD, Principal Scientist
Session Date and Time:
April 2, 2019 8:00 A.M – 12:00 P.M.
Poster Board Number:
Georgia World Congress Center, Exhibit Hall B, Poster Session 23
About OncoSec Medical Incorporated
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy platform – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. For more information, please visit www.oncosec.com.
ImmunoPulse® is a registered trademark of OncoSec Medical Incorporated.
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "can," "may," "will," "suggest," "look forward to," "potential," "understand," "anticipate," "believe," "estimate," "may," "expect" and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: uncertainties inherent in pre-clinical studies and clinical trials, such as the ability to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; our ability to raise additional funding necessary to fund continued operations; the success and timing of our clinical trials; the success and timing of our IND submission to the FDA; our ability to obtain and maintain marketing approval from regulatory agencies for our products in the U.S. and foreign countries; our ability to successfully implement our strategy; and the other factors discussed in OncoSec's filings with the Securities and Exchange Commission.
Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Stern Investor Relations
Scient Public Relations, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-poster-presentation-at-2019-american-association-for-cancer-research-annual-meeting-300803907.html
SOURCE OncoSec Medical Incorporated